Xanomeline/Trospium Chloride
The question
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with NICE and pharmaceutical manufacturers regarding the assessment and potential availability in England of xanomeline-trospium chloride (Cobenfy) for the treatment of schizophrenia.
Answered by Preet Kaur Gill
Department ministers and officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE), including in relation to the development of guidance on individual products.
Xanomeline-trospium chloride, also known as Cobenfy, has not yet been licensed by the Medicines and Healthcare products Regulatory Agency (MHRA). This means it cannot currently be marketed in the United Kingdom. NICE makes recommendations to the National Health Service on whether newly licensed medicines should be routinely funded, based on the evidence about how well they work and whether they provide value for money. NICE has already scheduled an appraisal of xanomeline tartrate–trospium chloride for treating schizophrenia, in case a UK licence is granted. NICE will aim to publish its guidance as close as possible to the expected licensing date.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →